Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (HKG: 0512) announced an exclusive collaboration agreement granting Grand Life Sciences commercialization rights to BBM-H803 in Mainland China, Hong Kong, Macau, and Taiwan. The AAV-based gene therapy for hemophilia A leverages Belief BioMed’s independent intellectual property and FDA Orphan Drug/Rare Pediatric Disease designations, combining BBM’s gene therapy innovation with Grand Life Sciences’ regional commercial infrastructure to accelerate patient access in Greater China.
Partnership Framework
Element
Detail
Parties
Belief BioMed (BBM) + Grand Life Sciences Group (HKG: 0512)
Agreement Type
Exclusive commercialization collaboration
Asset
BBM-H803 (AAV-based gene therapy for hemophilia A)
Territory
Greater China – Mainland China, Hong Kong, Macau, Taiwan
Strategic Goal
Accelerate commercialization; improve hemophilia A patient access; advance gene therapy industry development
Collaboration models gene therapy commercialization pathway for China biotech ecosystem
Development Timeline: Phase I/II data 2026–2027; pivotal China trial 2028; NDA filing 2029–2030 assuming positive durability data
Commercial Potential: One-time therapy pricing RMB 3–5 million (~$400,000–700,000) vs. lifetime prophylaxis cost; addressable market RMB 5–10 billion in Greater China
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical trial outcomes, regulatory approval timelines, and commercialization execution for BBM-H803 in Greater China. Actual results may differ due to gene therapy durability challenges, immunogenicity (AAV neutralizing antibodies), reimbursement negotiations for high-cost one-time therapies, and competitive entry from global gene therapy developers.-Fineline Info & Tech
By Fineline Cube 